NASDAQ:KPTI Karyopharm Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.17 +0.04 (+0.78%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$4.86▼$5.2650-Day Range$4.15▼$7.2352-Week Range$4.02▼$14.73Volume2.48 million shsAverage Volume2.44 million shsMarket Capitalization$410.60 millionP/E RatioN/ADividend YieldN/APrice Target$11.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Stock Forecast (MarketRank)Overall MarketRank™2.41 out of 5 starsMedical Sector188th out of 1,418 stocksPharmaceutical Preparations Industry76th out of 679 stocksAnalyst Opinion: 3.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 - 3.2 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.57, Karyopharm Therapeutics has a forecasted upside of 123.8% from its current price of $5.17.Amount of Analyst CoverageKaryopharm Therapeutics has received no research coverage in the past 90 days. Previous Next 4.9 Community Rank Outperform VotesKaryopharm Therapeutics has received 512 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKaryopharm Therapeutics has received 183 “underperform” votes. (Add your “underperform” vote.)Community SentimentKaryopharm Therapeutics has received 73.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote “Outperform” if you believe KPTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,153,045.00 in company stock.Percentage Held by Insiders10.24% of the stock of Karyopharm Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.75% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($2.06) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Karyopharm Therapeutics (NASDAQ:KPTI)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock News HeadlinesJune 22, 2022 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Fifty Day Moving Average of $6.05June 15, 2022 | finance.yahoo.comKaryopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase AgreementJune 15, 2022 | seekingalpha.comBiogen terminates 2018 asset purchase agreement with Karyopharm TherapeuticsJune 13, 2022 | seekingalpha.comKaryopharm director sells ~$3.4M in company sharesJune 12, 2022 | americanbankingnews.comDeepika Pakianathan Sells 325,977 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) StockJune 12, 2022 | americanbankingnews.comBrokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $11.57June 5, 2022 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Trading 8.2% Higher June 1, 2022 | finance.yahoo.comKaryopharm to Participate at the Jefferies Healthcare ConferenceMay 27, 2022 | msn.comLooking Into Karyopharm Therapeutics's Return On Capital EmployedMay 26, 2022 | finance.yahoo.comKaryopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual MeetingMay 26, 2022 | seekingalpha.comKaryopharm wins FDA’s Orphan Drug status for leading asset in myelofibrosisMay 25, 2022 | seekingalpha.comKaryopharm begins dosing in late-stage study of selinexor combo therapy for multiple myelomaMay 20, 2022 | seekingalpha.comEU drug regulator panel recommends expanding indication for Karyopharm's NexpovioSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees442Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today6/25/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$11.57 High Stock Price Forecast$22.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+123.8%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.470010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124.09 million Net Margins-46.14% Pretax Margin-46.03% Return on EquityN/A Return on Assets-37.92% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.11 Sales & Book Value Annual Sales$209.82 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-4.92Miscellaneous Outstanding Shares79,420,000Free Float71,286,000Market Cap$410.60 million OptionableOptionable Beta-0.16 Karyopharm Therapeutics Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares. View analyst ratings for Karyopharm Therapeutics or view top-rated stocks. What is Karyopharm Therapeutics' stock price forecast for 2022? 6 Wall Street analysts have issued 1 year price objectives for Karyopharm Therapeutics' shares. Their KPTI stock forecasts range from $6.00 to $22.00. On average, they predict Karyopharm Therapeutics' stock price to reach $11.57 in the next year. This suggests a possible upside of 123.8% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics or view top-rated stocks among Wall Street analysts. How has Karyopharm Therapeutics' stock price performed in 2022? Karyopharm Therapeutics' stock was trading at $6.43 at the start of the year. Since then, KPTI stock has decreased by 19.6% and is now trading at $5.17. View the best growth stocks for 2022 here. When is Karyopharm Therapeutics' next earnings date? Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Karyopharm Therapeutics. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) posted its earnings results on Thursday, May, 5th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.10. The firm had revenue of $47.67 million for the quarter, compared to analyst estimates of $34.78 million. During the same period in the previous year, the company posted ($0.77) EPS. View Karyopharm Therapeutics' earnings history. Who are Karyopharm Therapeutics' key executives? Karyopharm Therapeutics' management team includes the following people: Mr. Richard A. Paulson M.B.A., Pres, CEO & Director (Age 55, Pay $1.27M)Dr. Sharon Shacham M.B.A., Ph.D., Co-Founder & Chairman of Scientific Advisory Board (Age 52, Pay $766.54k)Mr. Michael P. Mason CPA, M.B.A., Exec. VP, CFO & Treasurer (Age 47, Pay $692.39k) (LinkedIn Profile)Mr. Ran Frenkel R.Ph., RPh, Exec. VP & Chief Devel. Officer (Age 53, Pay $667.87k)Dr. Mansoor Raza Mirza M.D., Clinical Consultant, Member of Scientific Advisory Board & Independent Director (Age 61, Pay $146.14k)Mr. Cameron Peters, VP of Fin., Assistant Treasurer & Principal Accounting Officer (Age 62)Mr. Pierre S. Sayad M.S., Ph.D., VP of Global Medical & Scientific AffairsMs. Elhan Webb C.F.A., Sr. VP of Investor RelationsMr. Michael J. Mano J.D., Sr. VP, Gen. Counsel & Sec. (Age 45)Ms. Lisa Meletta J.D., VP of Legal & Chief Compliance Officer What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees. Who are some of Karyopharm Therapeutics' key competitors? Some companies that are related to Karyopharm Therapeutics include Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), Amphastar Pharmaceuticals (AMPH), Dynavax Technologies (DVAX), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Cryoport (CYRX), Madrigal Pharmaceuticals (MDGL), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Sierra Oncology (SRRA), BELLUS Health (BLUSF), Myovant Sciences (MYOV) and Day One Biopharmaceuticals (DAWN). View all of KPTI's competitors. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (13.81%), BlackRock Inc. (9.98%), Palo Alto Investors LP (7.08%), Vanguard Group Inc. (4.99%), Rice Hall James & Associates LLC (1.69%) and Rice Hall James & Associates LLC (1.69%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Ran Frenkel, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Tanya Lewis. View institutional ownership trends for Karyopharm Therapeutics. Which major investors are selling Karyopharm Therapeutics stock? KPTI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Frontier Capital Management Co. LLC, Citigroup Inc., Group One Trading L.P., Simplex Trading LLC, Dupont Capital Management Corp, Allianz Asset Management GmbH, and Rhumbline Advisers. Company insiders that have sold Karyopharm Therapeutics company stock in the last two years include Christopher Brett Primiano, Deepika Pakianathan, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, and Tanya Lewis. View insider buying and selling activity for Karyopharm Therapeutics or view top insider-selling stocks. Which major investors are buying Karyopharm Therapeutics stock? KPTI stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Bank of America Corp DE, Vanguard Group Inc., Acadian Asset Management LLC, Candriam Luxembourg S.C.A., UBS Group AG, Victory Capital Management Inc., and Palo Alto Investors LP. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree. View insider buying and selling activity for Karyopharm Therapeutics or or view top insider-buying stocks. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $5.17. How much money does Karyopharm Therapeutics make? Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $410.60 million and generates $209.82 million in revenue each year. The company earns $-124.09 million in net income (profit) each year or ($1.470010) on an earnings per share basis. How many employees does Karyopharm Therapeutics have? Karyopharm Therapeutics employs 442 workers across the globe. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for Karyopharm Therapeutics is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at [email protected]. This page (NASDAQ:KPTI) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here